• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOTRONIK AG, BUELACH, SWITZERLAND ORSIRO 3.0/15; CORONARY DRUG-ELUTING STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOTRONIK AG, BUELACH, SWITZERLAND ORSIRO 3.0/15; CORONARY DRUG-ELUTING STENT Back to Search Results
Model Number 364484
Device Problem Patient Device Interaction Problem (4001)
Patient Problems Bradycardia (1751); Thrombosis/Thrombus (4440)
Event Date 04/30/2021
Event Type  Injury  
Manufacturer Narrative
Combination product: yes.
 
Event Description
Three orsiro drug-eluting stent systems were selected for treatment of a lesion (80-90 percent stenosis degree) in the distal rca/om.On (b)(6) 2021 the lesion was treated amongst others with an orsiro 3.0/15 with good results.The next day the patient went into vasovagal attack with bradycardia and hypotension.A control pci was conducted and multiple thrombosis were detected.Several aspirations were done with very good result.An intraaortic balloon pump (iabp) was implanted.The other two orsiro stents are reported separately.
 
Manufacturer Narrative
Combination product: yes according to the case description the patient underwent successfully a percutaneous coronary intervention with 3 orsiro drug-eluting stents to the rca and om.The day after the patient went into vasovagal attack with bradycardia and hypotension, the coronary angiography revealed a thrombotic occlusion of the vessel segments treated the day before.The device itself was not returned to biotronik and could therefore not be subjected to a technical investigation.However, the provided operative report and the angiographic material were reviewed to identify a potential technical complication or device malfunction.Further the production documentation of both products was reviewed to establish whether a deviation from the manufacturing process could be the cause for this event.Review of the production documentation for the product detailed above confirmed that both devices were manufactured according to specifications and fulfilled all the requirements of in-process and final inspection.Based on the reviewed documentation and the conducted investigation no device deficiency or manufacturing related root cause could be identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ORSIRO 3.0/15
Type of Device
CORONARY DRUG-ELUTING STENT
Manufacturer (Section D)
BIOTRONIK AG, BUELACH, SWITZERLAND
ackerstrasse 6
buelach CH-81 80
CH  CH-8180
MDR Report Key11848270
MDR Text Key251400376
Report Number1028232-2021-02724
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)Y
PMA/PMN Number
P170030
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Type of Report Initial,Followup
Report Date 05/19/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received05/19/2021
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date10/09/2022
Device Model Number364484
Device Catalogue NumberSEE MODEL NO.
Device Lot Number09205031
Was Device Available for Evaluation? No
Date Manufacturer Received07/14/2021
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
-
-